Description: EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
Home Page: www.kiorapharma.com
KPRX Technical Analysis
1371 East 2100 South
Salt Lake City,
UT
84105
United States
Phone:
781 788 8869
Officers
| Name | Title |
|---|---|
| Dr. Brian M. Strem Ph.D. | Pres, CEO, Principal Financial & Accounting Officer and Director |
| Dr. Eric J. Daniels M.B.A., M.D. | Chief Devel. Officer |
| Dr. Stefan Sperl Ph.D. | Exec. VP of CMC & Operations |
| Ms. Melissa Tosca | Exec. VP of Fin. |
| Dr. MaryJane Rafii Ph.D. | Consultant |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3451 |
| Price-to-Sales TTM: | 535.5867 |
| IPO Date: | 2015-07-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |